Even though Arvinas and Pfizer appear to have "written off" the drug, in one analyst's view, Rigel believes it can drive adoption among community-treated patients lacking SERD access.

Although the oncology community is buzzing with the potential of circulating tumor DNA (ctDNA) to revolutionize breast cancer ...

DNA liquid biopsies detect breast cancer at molecular levels to guide personalized therapy and monitor for recurrence or ...

With the help of DNA testing company Natera and its personalized molecular residual disease (MRD) blood test Signatera, Roche ...

A blood test that detects tumor DNA circulating in the bloodstream may help select the most effective treatment options for ...

Kelly, MD, MBA, and participants discussed key considerations for biomarker testing in upper GI cancers. Biomarker status has a significant impact on treatment selection for unresectable advanced ...

Health-evidence reviewers reverse recommendation on a blood test that detects a biomarker of a common cancer after decades of ...

I’ve spent much of my career thinking about one central question in oncology: how do we give patients clearer answers about their cancer? In the clinic, those questions are often simple but profound.

Genomic profiling can help personalize cancer care, but patients may not be offered these tests due to a burdensome ...

Data presented for a new NeXT Personal feature for monitoring resistance mutations Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, today announced the successful ...

The vision of a single blood test that could screen for dozens of different cancers has tantalized oncologists for more than a decade. Subscribe to read this story ad-free Get unlimited access to ...